This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Lee, A. M. Articles by Tyndale, R. F. Search for Related Content PubMed PubMed Citation Articles by Lee, A. M. Articles by Tyndale, R. F. Social Bookmarking                   What's this?

Drugs and genotypes: how pharmacogenetic information could improve smoking cessation treatment

Rachel F. Tyndale

Centre for Addiction and Mental Health, Department of Pharmacology, University of Toronto, Toronto, Canada

Current smoking cessation treatments are not optimal as the long-term abstinence rates are low. Nicotine replacement therapy and bupropion are the only pharmacotherapies widely available to smokers and there is a need to improve current cessation treatments and to develop new drug therapies. Our goal is to use pharmacogenetic information to improve smoking cessation treatments. Candidate genes include those involved in central mechanisms (such as genes encoding the nicotinic acetylcholine receptors, dopamine receptors, dopamine transporters and opioid receptors) and peripheral mechanisms (such as genes encoding the drug-metabolizing enzymes CYP2A6 and CYP2B6). Pharmacogenetics could be used to improve current smoking cessation treatments through two general approaches. The first would be to identify novel drug targets based on genetic variants that are associated with a natural protection against nicotine dependence, decreased smoking behaviour and/or increased smoking cessation. This knowledge could be used to develop drugs that can mimic these advantages, reducing the risk for acquisition, block the rewarding effects of smoking, decreasing the amount smoked and increasing cessation. The second would be to identify smokers with particular genetic variants who are likely to respond better to one treatment (or dose) versus another and to individualize their treatment to maximize long-term abstinence. This review will highlight examples of how pharmacogenetic information from central and peripheral candidate genes could contribute to improving smoking cessation outcomes by these two approaches.

Key Words: smoking cessation • pharmacogenetics • nicotine replacement therapy • bupropion • dopamine D2 receptor • SLC6A3 • CYP2A6 • CYP2B6 • OPRM1

Journal of Psychopharmacology, Vol. 20, No. 4 suppl, 7-14 (2006)
DOI: 10.1177/1359786806066039


CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				S. J. Tebbutt, A. James, and P. D. Pare Single-Nucleotide Polymorphisms and Lung Disease: Clinical Implications Chest, April 1, 2007; 131(4): 1216 - 1223. [Abstract] [Full Text] [PDF]

				W. D Hall A research agenda for assessing the potential contribution of genomic medicine to tobacco control Tob. Control, February 1, 2007; 16(1): 53 - 58. [Abstract] [Full Text] [PDF]